Myriad Genetics | MYGN - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
Agilent USD 990M 44M 2026-03
Becton, Dickinson and Co. USD 2.15B 257M 2026-03
Bio-Rad Laboratories USD 345.2M 1.8M 2025-12
Bruker USD 379.8M 69.4M 2026-03
Danaher USD 3.61B 20M 2026-06
Illumina USD 721M 38M 2026-03
J&J USD 18.55B 1.31B 2026-06
Mettler Toledo International USD 675.44M 65.98M 2025-12
Myriad Genetics USD 146.8M 3M 2025-12
OraSure Technologies USD 11.34M 435K 2025-12
Pacific Biosciences Of California USD 15.74M 601K 2025-12
Quest Diagnostics USD 906M 33M 2026-03
Quidel USD -91.8M 366.6M 2026-03
Repligen USD 108.28M 4.45M 2026-03
Revvity USD 387.66M 34M 2026-03
Standard Biotools USD 11.31M 74K 2026-03
Thermo Fisher Scientific USD 4.49B 146M 2026-03
Veracyte USD 101.16M 814K 2026-03
Waters USD 542M 15.42M 2026-03